AXQ Capital’s Amicus Therapeutics FOLD Stock Holding History

AXQ Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,128	Closed	-$158K	–	1091
2025 Q4	$158K	Buy	+11,128	New	+$109K	0.04%	609
2025 Q3	–	Sell	-50,548	Closed	-$290K	–	665
2025 Q2	$290K	Buy	+50,548	New	+$326K	0.09%	366
2025 Q1	–	Sell	-18,126	Closed	-$171K	–	554
2024 Q4	$171K	Buy	+18,126	New	+$188K	0.08%	345
2023 Q2	–	Sell	-23,030	Closed	-$255K	–	398
2023 Q1	$255K	Buy	+23,030	New	+$284K	0.1%	342

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

AXQ Capital's FOLD Position: Q1 2026 in Review

AXQ Capital sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 11,128 shares — an estimated $158K sold.

AXQ Capital first reported a position in FOLD in Q1 2023 and held it in 4 quarters. The position peaked at $290K in Q2 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

AXQ Capital reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
AXQ Capital sold 11,128 Amicus Therapeutics shares in Q1 2026, an estimated $158K.
AXQ Capital first reported a position in Amicus Therapeutics in Q1 2023 and held it in 4 quarters.
AXQ Capital's Amicus Therapeutics position peaked at $290K in Q2 2025.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.